SMTL ID : 2yfx.1

Structure of L1196M Mutant Anaplastic Lymphoma Kinase in Complex with Crizotinib

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 1.70 Å

Oligo State

monomer

Ligands

1 x VGH: 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine(Non-covalent)

VGH.1: 14 residues within 4Å: Chain A: L.38, A.64, M.112, E.113, L.114, M.115, A.116, G.117, G.118, R.169, N.170, L.172, G.185, D.186 6 PLIP interactions: 6 interactions with chain A Hydrophobic interactions: A:L.38, A:L.172 Hydrogen bonds: A:E.113, A:M.115 Water bridges: A:D.119 Halogen bonds: A:G.185

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Huang, Q. et al., Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib. J.Med.Chem. (2014)

Release Date

2011-05-04

Peptides

TYROSINE-PROTEIN KINASE RECEPTOR: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

TYROSINE-PROTEIN KINASE RECEPTOR

Related Entries With Identical Sequence